Matrix metalloproteinase biology applied to vitreoretinal disorders

British Journal of Ophthalmology

Volumn 84, Issue 6, 2000, Pages 654-666

  Sethi, C S ^a   Bailey, T A ^b   Luthert, P J ^b   Chong, N H V ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; CYTOKINE; GROWTH FACTOR; MATRILYSIN; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

EXTRACELLULAR MATRIX; HUMAN; PRIORITY JOURNAL; REVIEW; VITREORETINOPATHY;

EYE DISEASES; HUMANS; MATRIX METALLOPROTEINASES; MELANOMA; RETINAL NEOVASCULARIZATION; TISSUE INHIBITOR OF METALLOPROTEINASES; UVEAL NEOPLASMS; VITREORETINOPATHY, PROLIFERATIVE;

EID: 0034088547     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.84.6.654     Document Type: Review

References (167)

1. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
2. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10:602-8.
3. Moses MA, Marikovsky M, Harper JW, et al. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem 1996;60:379-86.
4. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatol 1997;21:1-12.
5. Brown PD. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol 1997;14:1-10.
6. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
7. Brown PD. Clinical studies with matrix metalloproteinase inhibitors. APMIS 1999;107:174-80.
8. Pilcher BK, Wang M, Qin X-J, et al. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann NY Acad Sci 1999;878:12-24.
9. Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
10. Cawston TE, Billington C. Metalloproteinases in the rheumatic diseases. J Pathol 1996;180:115-7.
11. Murphy G, Docherty AJP, Hembry RM, et al. Metalloproteinases and tissue damage. Br J Rheumatol 1991;30(suppl 1): 25-31.
12. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol 1997;6:199-213.
13. Sorsa T, Mantyla P, Ronka H, et al. Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Ann NY Acad Sci 1999;878:130-49.
14. Vaalamo M, Weckroth M, Puolakkainen P, et al. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol 1996;135:52-9.
15. Nwomeh BC, Liang HX, Cohen IK, et al. MMP-8 is the predominant collagenase in healing wounds and non-healing ulcers. J Surg Res 1999;81:189-95.
16. Kossakowska AE, Edwards DR, Lee SS, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998;153:1895-902.
17. Fukuda Y, Ishizaki M, Kudoh S, et al. Localisation of matrix metalloproteinases-1,-2 and -9and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest 1998;78:687-98.
18. Matila L, Airola K, Ahonen M, et al. Activation of TIMP-3 mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998;110:416-21.
19. Murate T, Yamashita K, Isogai C, et al. The production of TIMPs in megakaryopoesis: possible role of platelet-and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br J Haematol 1997;99:181-9.
20. Hembry RM, Ehrlich HP. Immunolocalisation of collagenases and TIMPs in hypertrophic scar tissue. Br J Dermatol 1986;115:409-20.
21. Massova I, Kotra LP, Fridman R, et al. Matrix metalloproteinases: structures, evolution and diversification. FASEB J 1998;12:1075-95.
22. Baramova E, Foidart J-M. Matrix metalloproteinase family. Cell Biol Int 1995;19:239-42.
23. Kleiner DE, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 1993;5:891-7.
24. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: why the 'hemopexin' domain? Matrix Biol 1997;15:511-8.
25. Seiki M. Membrane-type matrix metalloproteinases. APMIS 1999;107:137-43.
26. Pei D. Identification and characterisation of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem 1999;274:8925-32.
27. Murphy G, Knauper V, Cowell S, et al. Evaluation of some newer matrix metalloproteinases. Ann NY Acad Sci 1999;878:25-39.
28. Crawford HC, Matrisian LM. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 1996;49:20-37.
29. Murphy G. The regulation of connective tissue metalloproteinases by natural inhibitors. Agents Actions 1991;(suppl) 35:69-76.
30. Kahari VM, Saarialho-Kere U. Matrix metalloproteinase and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45.
31. Bond M, Fabunmi RP, Baker AH, et al. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998;435:29-34.
32. Murphy G, Ward R, Gavrilovic J, et al. Physiological mechanisms for metalloproteinase activation. Matrix 1992;suppl 1:224-230.
33. Hiraoka N, Allen E, Apel IJ, et al. Matrix metalloproteinases regulate neovascularisation by acting as pericellular fibrinolysins. Cell 1998;95:365-77.
34. Gomis-Ruth F-X, Maskos K, Betz M, et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997;389:77-81.
35. Fortunato SJ, Menon R, Lombardi SJ. Presence of four tissue inhibitors of metalloproteinases (TIMP-1, -2, -3 and -4) in human fetal membranes. Am J Reprod Immunol 1998;40:395-400.
36. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999;42:162-72.
37. Overall CM. Regulation of tissue inhibitor of matrix metalloproteinase expression. Ann NY Acad Sci 1994;732:51-64.
38. Leco KJ, Khokha R, Pavloff N, et al. TIMP-3 is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994;269:9352-60.
39. Hayakawa T, Yamashita K, Ohuchi E, et al. Cell growth-promoting activity of tissue inhibitor of metalloproteinse-2 (TIMP-2). J Cell Sci 1994;107: 2373-9.
40. Hayakawa T, Yamashita K, Tanzawa E, et al. Growth-promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells. FEBS Lett 1992;298:29-32.
41. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998;8:171-7.
42. Anderson K, Maelandsmo GM, Hovig E, et al. Interleukin-1 alpha and basic fibroblast growth factor induction of matrix metalloproteinases and their inhibitors in osteosarcoma cells is modulated by the metastasis associated protein CAPL. Anticancer Res 1998;18:3299-303.
43. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1 independent pathway of IL-1 beta processing. J Immunol 1998;161:3340-6.
44. Zhang Y, McCluskey K, Fujii K, et al. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol 1998;161:3071-6.
45. Johnatty RN, Taub DD, Reeder SP, et al. Cytokine and chemokine regulation of pro-MMP-9and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 1997;158:2327-33.
46. Matrisian LM, Ganser GL, Kerr LD, et al. Negative regulation of gene expression by TGF-beta. Mol Reprod Dev 1992;32:111-20.
47. Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899-904.
48. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;261:4337-45.
49. Connor TB, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-β type 2 levels in the eye. J Clin Invest 1989;83:1661-6.
50. Imai K, Hiramatsu A, Fukushima D, et al. Degradation of decorin by matrix metalloproteinase: identification of the cleavage sites, kinetic analyses and transforming growth factor-betal release. Biochem J 1997;322:809-14.
51. Rifkin DB, Mazzieri R, Munger JS, et al. Proteolyric control of growth factor availability. APMIS 1999;107:80-5.
52. McGeehan GM, Becherer JD, Bast RC, et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994;370:558-61.
53. Levi E, Fridman R, Miao HQ, et al. Matrix metalloproteinase-2 releases active soluble ectodomain of fibroblast growth factor receptor-1. Proc Natl Acad Sci USA 1996;93:7069-74.
54. Moss ML, Jin S-LC, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-α. Nature 1997;385: 733-6.
55. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour necrosis factor-α from cells. Nature 1997;385:729-33.
56. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999;11:614-621.
57. Streuli C. Extracellular matrix remodeling and cellular differentiation. Curr Opin Cell Biol 1999;11:634-40.
58. Fowlkes JL, Serra DM, Nagase H, et al. MMPs are IGFBP-degrading proteinases: implication for cell proliferation and tissue growth. Ann NY Acad Sci 1999;878:696-9.
59. Kieseier BC, Seifert T, Giovannoni G, et al. Matrix metalloproteinases in inflammatory demyelination. Neurology 1999;53:20-5.
60. Mun-Bryce S, Rosenberg GA. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 1998;274: R1203-11.
61. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-63.
62. Shapiro SD, Campbell EJ, Kobayashi DK, et al. Immune modulation of metalloproteinase production in human macrophages. J Clin Invest 1990;86:1204-10.
63. Ashley RA and the SDD Clinical Research Team. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. Ann NY Acad Sci 1999;878:335-46.
64. Zucker S, Hymowitz M, Connor C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Ann NY Acad Sci 1999;878:212-27.
65. Lein M, Nowak L, Jung K, et al. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem 1997;30:491-6.
66. Kanbe N, Tanaka A, Kanabe M, et al. Human mast cells produce matrix metalloproteinase-9. Eur J Immunol 1999;29:2645-9.
67. Arumugam S, Jang Y-C, Chen-Jensen C, et al. Temporal activity of plasminogen activators and matrix metalloproteinases during cutaneous wound repair. Surgery 1999;125:587-93.
68. Salo T, Makela M, Kylmaniemi M, et al. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 1994;70:176-82.
69. Di Colandrea T, Wang L, Wille J, et al. Epidermal expression of collagenase delays wound healing in transgenic mice. J Invest Dermatol 1998;111:1029-33.
70. Vaalaom M, Leivo T, Saarialho-Kere U. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1,-2,-3 and -4) in normal and aberrant wound healing. Hum Pathol 1999;30:795-802.
71. Kawashima Y, Saika S, Yamanaka O, et al. Immunolocalisation of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues. Curr Eye Res 1998;17:445-51.
72. Kumar R, Yoneda J, Bucana CD, et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 1998;12:749-57.
73. Moses MA. The regulation of neovascularisation by matrix metalloproteinases and their inhibitors. Stem Cells 1997;15:180-9.
74. Murphy AN, Unsworth EJ, Stetler-Stevenson WG, et al. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351-8.
75. Clark AF. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci 1998;39:2514-6.
76. Brooks PC, Silletti S, von Schalscha TL, et al. Disruption of angiogenesis by PEX, a non-catalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
77. Unemori EN, Ferrara N, Baurer EA, et al. Vascular endothetial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1991;153:557-62.
78. Garzetti GG, Ciavattini A, Lucarini G, et al. Expression of vascular endothelial growth factor related to 72-kilodalton immunostaining in patients with serous ovarian tumours. Cancer 1999;85:2219-25.
79. Cockett MI, Murphy G, Birch ML, et al. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 1998;63:295-313.
80. Zucker S. Experimental models to identify antimetastatic drugs: are we there yet? Ann NY Acad Sci 1999;878:208-11.
81. Fingleton BM, Goss KJH, Crawford HC, et al. Matrilysin in early stage intestinal tumorigenesis. APMIS 1999;107:102-10.
82. Ring P, Johansson K, Hoyhtya M, et al. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumour stage. Br J Cancer 1997;76:805-11.
83. Ahmad A, Hanby A, Dublin E, et al. Stromelysin-3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol 1997;152:721-8.
84. Vaisanen A, Killioinen M, Taskinen PJ, et al. Prognostic value of MMP-2 immunoreactive protein (72kD type IV collagenase) in primary skin melanoma. J Pathol 1998;186:51-8.
85. Brown PD. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat 1998;52:125-36.
86. Henriet P, Blavier L and Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999;107:111-9.
87. Blavier L, Henriet P, Imren S, et al. Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci 1999;878:108-19.
88. DeClerck YA, Perez N, Shimada H, et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-8.
89. Kruger A, Sanchez-Sweatman OH, Martin DC, et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 1998;16:2419-23.
90. Bramhall SR, Neoptolemos JP, Stamp GW, et al. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997;182:347-55.
91. Plantner JJ, Smine A, Qhinn TA. Matrix metalloproteinases and metalloproteinase inhibitors in human interphotoreceptor matrix and vitreous. Curr Eye Res 1998;17:132-40.
92. Padgett LC, Lui GM, Werb Z, et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: vectorial secretion and regulation. Exp Eye Res 1997;64:927-38.
93. Smine A, Plantner JJ. Membrane type-1 matrix metalloproteinase in human ocular tissues. Curr Eye Res 1997;16:925-9.
94. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 1995;79:953-60.
95. Scott KA, Wood EJ, Karran EH. A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. FEBS Lett 1998; 441:137-40.
96. Immonen I, Konttinen YT, Sorsa T, et al. Proteinases in subretinal fluid. Graefes Arch Clin Exp Ophthalmol 1996;234:105-9.
97. Matsuo T, Okada Y, Shiraga F, et al. TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid. Jpn J Ophthalmol 1998;42:377-80.
98. De La Paz MA, Itoh Y, Toth CA, et al. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci 1998;39:1256-60.
99. Alexander JP, Bradley JMB, Gabourel JD, et al. Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest Ophthalmol Vis Sci 1990;31:2520-8.
100. Kosnosky W, Li TH, Pakalnis VA, et al. Interleukin-1-β changes the expression of metalloproteinases in the vitreous humor and induces membrane formation in eyes with pre-existing retinal holes. Invest Ophthalmol Vis Sci 1994;35:4260-7.
101. Hunt RC, Fox A, Pakalnis VA, et al. Cytokines cause cultured retinal pigment epithelial cells to secrete metalloproteinases and to contract collagen gels. Invest Ophthalmol Vis Sci 1993;34:3179-86.
102. Webster L, Chignell AH, Limb GA. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. Exp Eye Res 1999;68:91-8.
103. Kolb SA, Lahrtz F, Paul R, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol 1998;84:143-50.
104. Norman JT, Clark IM, Garcia PL. Regulation of TIMP-1 expression by hypoxia in kidney fibroblasts. Ann NY Acad Sci 1999;878:503.
105. Limb GA, Miller K, Chignell AH, et al. Metalloproteinases and TIMP-1 in proliferative vitreoretinopathy. Biochem Soc Trans 1997;25:234S.
106. Kon CH, Occleston NL, Charteris DG, et al. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1998;39:1524-9.
107. Sethi CS, Limb GA, Charteris DG, et al. Differential expression of matrix metalloproteinases in normal and chronically detached retina. [ARVO Abstract] Invest Ophthalmol Vis Sci 1999;40:S950.
108. Ozerdem U, Cheng LY, Mach-Hofacre B, et al. The effect of AG3340 a potent inhibitor of matrix metalloproteinase on a subacute model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1999;40:S974.
109. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained release triamcinolone and 5-fluorouracil co-drug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998;116:69-77.
110. Grant MB, Caballero S, Tarnuzzer RW, et al. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 1998;47:1311-7.
111. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999;40:809-13.
112. Jackson DW, McGuire PG, Eriqat C, et al. Both vascular endothelial growth factor (VEGF) and hypoxia increase gelatinase A (MMP-2) activity in vascular endothelial cells in vitro. [ARVO Abstract] Invest Ophthalmol Vis Sci 1997;38:S500.
113. Kosano H, Okano T, Katsura Y, et al. ProMMP-2 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 1999;64:2307-15.
114. Das A, McLamore A, Song W, et al. Retinal neovascularisation is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 1999;117:498-503.
115. Sawicki G, Sanders EJ, Salas E, et al. Localisation and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost 1998;80: 836-9.
116. Ryan ME, Ramamurthy MS, Sorsa T, et al. MMP-mediated events in diabetes. Ann NY Acad Sci 1999;878:311-34.
117. Morimoto Y, Nishikawa K, Ohashi M. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumour necrosis factor alpha production. Life Sci 1997;61:795-803.
118. McLennan SV, Death AK, Fisher EJ, et al. The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy. Cell Mol Biol 1999;45:123-35.
119. Ebihara I, Nakamura T, Shimada N, et al. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1998;32:544-50.
120. Mooy CM, de Jong PTVM. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 1996;41:215-28.
121. Mueller BM. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 1996;212:65-80.
122. Vaisanen A, Kallioinen M, von Dickhoff K, et al. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - a new prognostic marker in uveal melanoma? J Pathol 1999;188:56-62.
123. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumour invasion. FASEB J 1999;13:781-92.
124. Lee KS, Rha SY, Kim SJ, et al. Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis 1996;14:512-9.
125. Werb Z, Vu TH, Rinkenberger JL, et al. Matrix-degrading proteases and angiogenesis during development and tumour formation. APMIS 1999; 107:11-18.
126. Brown PD. Synthetic inhibitors of matrix metalloproteinases. In: Parks WC, Mecham RP, eds. Matrix metalloproteinases. San Diego: Academic Press, 1998:249-52.
127. Anand-Apte B, Bao L, Smith R, et al. A review of tissue inhibitor of metalloproteinase-3 (TIMP-3) and experimental analysis of its effect on primary tumour growth. Biochem Cell Biol 1996;74:853-62.
128. Brown PD. Clinical studies with matrix metalloproteinase inhibitors. APMIS 1999;107:174-80.
129. Lokeshwar BL. MMP inhibition in prostate cancer. Ann NY Acad Sci 1999;878:271-89.
130. Fariss RN, Apte SS, Olsen BR, et al. Tissue inhibitor of metaloproteinase-3 is a component of Bruch's membrane of the eye. Am J Pathol 1997;150:323-8.
131. Vranka JA, Johnson E, Zhu X, et al. Discreet expression and distribution pattern of TIMP-3 in the human retina and choroid. Curr Eye Res 1997;16: 102-10.
132. Anande-Apte B, Pepper MS, Voest E, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 1997;38: 817-23.
133. Wang X, Tromp G, Cole CW, et al. Analysis of coding sequences for tissue inhibitor of metalloproteinase 1 (TIMP1) and 2 (TIMP2) in patients with aneurysms. Matrix Biol 1999;18:121-4.
134. Sorsby A, Mason MEJ, Gardener N. A fundus dystrophy with unusual features. Br J Ophthalmol 1949;33:61-97.
135. Chong NHV, Alexander RA, Gin T, et al. TIMP-3, collagen and elastin immunohistochemistry and histopathology of Sorsby's fundus dystrophy. Invest Ophthalmol Vis Sci 2000;41:898-908.
136. Weber BH, Vogt G, Pruett RC, et al. Mutations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994;8:352-6.
137. Felbor U, Stohr H, Amann T, et al. A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP-3) in Sorsby's fundus dystrophy. J Med Genet 1996;33:233-6.
138. Jacobson SG, Cideciyan AV, Regunath G, et al. Night blindness in Sorsby's fundus dystrophy reversed by vitamin A. Nat Genet 1995;11:27-32.
139. Apte SS, Mattei MG, Olsen BR. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinase-3 (TIMP-3) and mapping of the TIMP-3 gene to chromosome 22. Genomics 1994;19:86-90.
140. Langton KP, Barker MD, McKie N. Localisation of the functional domains of human tissue inhibitor of metalloproteinase-3 and the effects of a Sorsby's fundus dystrophy mutation. J Biol Chem 1998;273:16778-81.
141. Fariss RN, Apte SS, Luthert PJ, et al. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Br J Ophthalmol 1998;82:1329-34.
142. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol 1996;80:2.
143. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
144. Felbor U, Doepner D, Schneider U, et al. Evaluation of the gene encoding the tissue inhibitor of metalloproteinases-3 in various maculopathies. Invest Ophthalmol Vis Sci 1997;38:1054-9.
145. De La Paz MA, Pericak-Vance MA, Lennon F, et al. Exclusion of TIMP-3 as a candidate locus in age-related macular degeneration. Invest Ophthalmol Vis Sci 1997;38:1060-5.
146. Kamei M, Hollyfield JG. TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci 1999;40:2367-75.
147. Zeiss CJ, Acland GM, Aguirre GD, et al. TIMP-1 expression is increased in X-linked progressive retinal atrophy despite its exclusion as a candidate gene. Gene 1998;225:67-75.
148. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularisation. Ophthalmology 1996;103:1260-70.
149. Plantner JJ, Jiang C, Smine A. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp Eye Res 1998;67:637-45.
150. Guo L, Hussain AA, Limb GA, et al. Age-dependent variation in metalloproteinase activity of isolated human Bruch's membrane and choroid. Invest Ophthalmol Vis Sci 1999;40:2676-82.
151. Ali RR, Reichel MB, Hunt DM, et al. Gene therapy for inherited retinal degeneration. Br J Ophthalmol 1997;81:795-801.
152. Ho AC, Maguire MG, Yoken J, et al. Laser-induced drusen reduction improves visual function at 1 year. Ophthalmology 1999;106:1367-74.
153. Ormerod LD, Puklin JE, Frank RN. Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration. Ophthalmology 1994;101:1201-10.
154. Adelberg DA, Del Priore LV, Kaplan HJ. Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders. Retina 1995;15:198-205.
155. Steen B, Sejersen S, Berglin L, et al. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1998;39:2194-200.
156. Adachi Y, Itoh F, Yamamoto H, et al. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers. Int J Oncol 1998;13:1031-5.
157. Kadonosono K, Yazama F, Itoh N, et al. Expression of matrix metalloproteinase-7 in choroidal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1999;128:382-4.
158. Garcia CR, Rivero ME, Hagedorn M, et al. Efficacy of AG3340, a selective inhibitor of matrix metalloproteases in an animal model of retinal neovascularization. [ARVO Abstract] Invest Ophthalmol Vis Sci 1999;40:S617.
159. Shalinsky DR, Brekken J, Zou H, et al. Broad anti-tumour abd anti-angiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 1999;878: 236-70.
160. Rivero ME, Garcia CR, McDermott CD, et al. Intraocular properties of AG3340, a selective matrix metalloproteinase inhibitor with anti-angiogenic activity. [ARVO Abstract] Invest Ophthalmol Vis Sci 1998;39: S585.
161. Collier MA, Yuen GJ, Bansal SK, et al. A phase I study of the matrix metalloproteinase inhibitor AG3340 given in single doses to healthy volunteers. Proc Am Assoc Cancer Res 1997;38:A1491.
162. Heller RA, Schena M, Chai A, et al. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA 1997;94:2150-5.
163. Spirin KS, Ljubimov AV, Castellon R, et al. Analysis of gene expression in human bullous keratopathy corneas containing limiting amounts of RNA. Invest Ophthalmol Vis Sci 1999;40:3108-15.
164. Peng KW, Morling FJ, Cosset FL, et al. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 1997;8: 729-38.
165. Hua J, Mushel RG. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996;56:5279-84.
166. Woessner JF. Matrix metalloproteinase inhibition: from the Jurassic to the third millenium. Ann NY Acad Sci 1999;878:388-403.
167. Shapiro SD. Mighty mice: transgenic technology "knocks out" questions of matrix metalloproteinase function. Matrix Biol 1997;15:527-33.